RxDoctor Payments Data

Jeff Pan, MD

Urology · Falls Church, VANPI 1437261138

Payments from drug & device makers

$985in general payments, 2019–2025

Across 28 payments — averaging $35.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$444
  • Astellas Pharma US Inc$185
  • Endo Pharmaceuticals Inc.$158
  • AstraZeneca$75
  • Pfizer$70
  • Procept Biorobotics Corporation$22
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$94496%
  • Education$414%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)8$444
Astellas Pharma US Inc5$185
Endo Pharmaceuticals Inc.7$158
AstraZeneca1$75
Pfizer4$70
Procept Biorobotics Corporation1$22
Urogen Pharma, Inc.1$18
Metuchen Pharmaceuticals1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$985 in reported general payments places this provider in the 30th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$66,652
Medicare patients
139
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron12$5,888
Potassium Citrate ErPotassium Citrate34$5,814
Tamsulosin Hcl364$4,413
Oxybutynin Chloride ErOxybutynin Chloride112$2,097
Finasteride167$1,987
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst123$1,774
Dutasteride15$638
Alfuzosin Hcl ErAlfuzosin Hcl13$380
Allopurinol25$332
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen40$233
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav32$201
Terazosin Hcl16$197
Clotrimazole13$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$185$5,88812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 300 urology providers in Virginia.

Other urology in Falls Church

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →